These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 27350399)

  • 1. Cucurbitacin B reverses multidrug resistance by targeting CIP2A to reactivate protein phosphatase 2A in MCF-7/adriamycin cells.
    Cai F; Zhang L; Xiao X; Duan C; Huang Q; Fan C; Li J; Liu X; Li S; Liu Y
    Oncol Rep; 2016 Aug; 36(2):1180-6. PubMed ID: 27350399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cucurbitacin B induces autophagy and apoptosis by suppressing CIP2A/PP2A/mTORC1 signaling axis in human cisplatin resistant gastric cancer cells.
    Liu X; Duan C; Ji J; Zhang T; Yuan X; Zhang Y; Ma W; Yang J; Yang L; Jiang Z; Yu H; Liu Y
    Oncol Rep; 2017 Jul; 38(1):271-278. PubMed ID: 28534965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cucurbitacin B induces inhibitory effects via CIP2A/PP2A/Akt pathway in glioblastoma multiforme.
    Qin S; Li J; Si Y; He Z; Zhang T; Wang D; Liu X; Guo Y; Zhang L; Li S; Li Q; Liu Y
    Mol Carcinog; 2018 Jun; 57(6):687-699. PubMed ID: 29393542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer.
    Liu P; Xiang Y; Liu X; Zhang T; Yang R; Chen S; Xu L; Yu Q; Zhao H; Zhang L; Liu Y; Si Y
    Molecules; 2019 Feb; 24(3):. PubMed ID: 30759826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cucurbitacin B induces inhibitory effects via the CIP2A/PP2A/C-KIT signaling axis in t(8;21) acute myeloid leukemia.
    Ma W; Xiang Y; Yang R; Zhang T; Xu J; Wu Y; Liu X; Xiang K; Zhao H; Liu Y; Si Y
    J Pharmacol Sci; 2019 Apr; 139(4):304-310. PubMed ID: 30852180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CIP2A silencing alleviates doxorubicin resistance in MCF7/ADR cells through activating PP2A and autophagy.
    Zhu Z; Wei Z
    Clin Transl Oncol; 2021 Aug; 23(8):1542-1548. PubMed ID: 33948919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arctigenin inhibits triple-negative breast cancers by targeting CIP2A to reactivate protein phosphatase 2A.
    Huang Q; Qin S; Yuan X; Zhang L; Ji J; Liu X; Ma W; Zhang Y; Liu P; Sun Z; Zhang J; Liu Y
    Oncol Rep; 2017 Jul; 38(1):598-606. PubMed ID: 28560452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CIP2A is a target of bortezomib in human triple negative breast cancer cells.
    Tseng LM; Liu CY; Chang KC; Chu PY; Shiau CW; Chen KF
    Breast Cancer Res; 2012 Apr; 14(2):R68. PubMed ID: 22537901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increase in CIP2A expression is associated with doxorubicin resistance.
    Choi YA; Park JS; Park MY; Oh KS; Lee MS; Lim JS; Kim KI; Kim KY; Kwon J; Yoon DY; Moon EY; Yang Y
    FEBS Lett; 2011 Mar; 585(5):755-60. PubMed ID: 21241697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells.
    Chen KF; Liu CY; Lin YC; Yu HC; Liu TH; Hou DR; Chen PJ; Cheng AL
    Oncogene; 2010 Nov; 29(47):6257-66. PubMed ID: 20729919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A.
    Yu HC; Hung MH; Chen YL; Chu PY; Wang CY; Chao TT; Liu CY; Shiau CW; Chen KF
    Cell Death Dis; 2014 Jul; 5(7):e1359. PubMed ID: 25077545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
    Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
    EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma.
    Yu HC; Chen HJ; Chang YL; Liu CY; Shiau CW; Cheng AL; Chen KF
    Biochem Pharmacol; 2013 Feb; 85(3):356-66. PubMed ID: 23178652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cucurbitacin D induces cell cycle arrest and apoptosis by inhibiting STAT3 and NF-κB signaling in doxorubicin-resistant human breast carcinoma (MCF7/ADR) cells.
    Ku JM; Kim SR; Hong SH; Choi HS; Seo HS; Shin YC; Ko SG
    Mol Cell Biochem; 2015 Nov; 409(1-2):33-43. PubMed ID: 26169986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genistein targets the cancerous inhibitor of PP2A to induce growth inhibition and apoptosis in breast cancer cells.
    Zhao Q; Zhao M; Parris AB; Xing Y; Yang X
    Int J Oncol; 2016 Sep; 49(3):1203-10. PubMed ID: 27574003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells.
    Liu CY; Hung MH; Wang DS; Chu PY; Su JC; Teng TH; Huang CT; Chao TT; Wang CY; Shiau CW; Tseng LM; Chen KF
    Breast Cancer Res; 2014 Sep; 16(5):431. PubMed ID: 25228280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib sensitizes HCC cells to CS-1008, an antihuman death receptor 5 antibody, through the inhibition of CIP2A.
    Chen KF; Yu HC; Liu CY; Chen HJ; Chen YC; Hou DR; Chen PJ; Cheng AL
    Mol Cancer Ther; 2011 May; 10(5):892-901. PubMed ID: 21393428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes.
    Niemelä M; Kauko O; Sihto H; Mpindi JP; Nicorici D; Pernilä P; Kallioniemi OP; Joensuu H; Hautaniemi S; Westermarck J
    Oncogene; 2012 Sep; 31(39):4266-78. PubMed ID: 22249265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FL118 inhibits viability and induces apoptosis of colorectal cancer cells via inactivating the CIP2A/PP2A axis.
    Lin X; Gao M; Zhang A; Tong J; Zhang X; Su Q; Yang Z; Gao H; Jiang G
    Life Sci; 2019 Dec; 239():117074. PubMed ID: 31751585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CIP2A is associated with multidrug resistance in cervical adenocarcinoma by a P-glycoprotein pathway.
    Liu J; Wang M; Zhang X; Wang Q; Qi M; Hu J; Zhou Z; Zhang C; Zhang W; Zhao W; Wang X
    Tumour Biol; 2016 Feb; 37(2):2673-82. PubMed ID: 26404133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.